Revance Shares Fall on Failing to Bag FDA Approval




  • In Business
  • 2021-10-18 11:37:12Z
  • By SmarterAnalyst

Shares of Revance Therapeutics, Inc. (RVNC) dropped 33.1% in Friday's extended trade and another 32% at the time of writing after the company announced that the Food and Drug Administration (FDA) declined to approve its injectable drug, DaxibotulinumtoxinA, to treat moderate to severe glabellar (frown) lines.

The biotechnology company engages in the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. (See Revance stock charts on TipRanks)

FDA has reasoned that some shortcomings were identified in the Revance's manufacturing facility during the onsite inspection. Notably, no product-related deficiencies have been mentioned in the Complete Response Letter. The company seeks to request a Type A meeting with the FDA to address the deficiencies.

The President and CEO of Revance, Mark Foley, said, "We are very disappointed by this unanticipated response from the FDA and are seeking further clarity from the agency. We remain committed to bringing our next-generation neuromodulator product to market in both aesthetic and therapeutic indications."

Following the news, Mizuho Securities analyst Vamil Divan maintained a Buy rating on Revance and lowered the price target to $26 from $36. The new price target implies 14.5% upside potential from current level. (See Analysts' Top Stocks on TipRanks)

Divan noted, "We spoke to management over the weekend and assume this will likely mean a delay of about 12-15 months, but also believe Daxi is still approvable and will ultimately have an important role in the aesthetics and therapeutic toxin market."

Consensus among analysts is a Strong Buy based on 7 unanimous Buys. The average Revance price target of $25.50 implies upside potential of 12.3%.

Investors should always be aware of the risks involved in any stock. According to the new TipRanks' Risk Factors tool, RVNC is at risk mainly because of three factors: Legal and Regulatory, Finance and Corporate, and Tech & Innovation, which contribute 28%, 22% and 21%, respectively, to the total 67 risks identified for the stock. Under the Legal & Regulatory risk category, Revance has 19 risks, details of which can be found on the TipRanks website.

 

Related News:
Bank of America Reports Upbeat Q3 Results
Citigroup Q3 Results Beat Street Expectations
Corsair Expects Q3 Revenues to Miss Consensus Estimates; Shares Fall

More recent articles from Smarter Analyst:

  • Badger Meter Q3 Results Beat Expectations

  • Goldman Sachs Q3 Results Outperform; Shares Jump 3.8%

  • J.B. Hunt Exceeds Q3 Expectations; Shares Hit All-Time High

  • Truist Financial Posts Strong Q3 Results; Shares Rise 1.2%

COMMENTS

More Related News

These Brand New Retail Stocks Look Compelling, Say Analysts
These Brand New Retail Stocks Look Compelling, Say Analysts

Despite the expectation for record-breaking ecommerce sales for the full holiday season, things have gotten off to a shaky start. Both Black Friday's and...

Omicron complicates puzzle over at-home Covid pill
Omicron complicates puzzle over at-home Covid pill

Independent advisers to the FDA endorsed the pill, molnupiravir, in an unusually tight 13-10 vote this week after airing concerns about its low efficacy rate and potential safety risks to pregnant people.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • DASAPK
    (2021-10-18 14:19:52Z)

    يتم التحميل التطبيق بصيغة apk للاندرويد مجانا عبر الضغط على ايقونة التحميل فوق اعلاه وسيتم التحميل بشكل مجاني وامن

    REPLY

Top News: Business